SCHEMBL3540352

SCHEMBL3540352

CC1CCN(c2cc(N3CCOCC3)ccc2C(N)=O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
MAPT P10636 4/20 0.53
CSF1R P07333 1/20 0.53
LGMN Q99538 3/20 0.51
PRKDC P78527 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
USP2 O75604 1/20 0.48
PARP1 P09874 1/20 0.47
JAK2 O60674 2/20 0.45
JAK1 P23458 2/20 0.45
TYK2 P29597 2/20 0.45
JAK3 P52333 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
CTPS1 P17812 1/20 0.44
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538621 0.86 CSF1R (0.51) ALDH1A1MAPTCSF1RLGMNSMN1; SMN2
SCHEMBL3958572 0.85 CSF1R (0.52) ALDH1A1MAPTCSF1RLGMNSMN1; SMN2
SCHEMBL3536839 0.84 MAPT (0.56) ALDH1A1MAPTLGMNPRKDCSMN1; SMN2
SCHEMBL3539721 0.84 CSF1R (0.51) ALDH1A1MAPTCSF1RSMN1; SMN2USP2
SCHEMBL3537507 0.82 CSF1R (0.54) ALDH1A1MAPTCSF1RSMN1; SMN2USP2
SCHEMBL3966405 0.81 CSF1R (0.55) ALDH1A1MAPTCSF1RLGMNSMN1; SMN2
SCHEMBL3540354 0.80 LGMN (0.77) ALDH1A1MAPTCSF1RLGMNSMN1; SMN2
SCHEMBL16341594 0.79 ALDH1A1 (0.48) ALDH1A1MAPTSMN1; SMN2USP2MEN1
SCHEMBL3962010 0.79 KDM4E (0.54) ALDH1A1MAPTCSF1RLGMNSMN1; SMN2
Trifluoroacetic Acid SCHEMBL3539634 0.78 CSF1R (0.46) ALDH1A1MAPTCSF1RSMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US claimed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP claimed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885CSF1R 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.